Mon, April 19, 2021

Matthew Harrison Maintained (SRPT) at Hold with Decreased Target to $93 on, Apr 19th, 2021

Matthew Harrison of Morgan Stanley, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Decreased Target from $95 to $93 on, Apr 19th, 2021.

Matthew has made no other calls on SRPT in the last 4 months.



There are 9 other peers that have a rating on SRPT. Out of the 9 peers that are also analyzing SRPT, 4 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Joel Beatty of "Citigroup" Downgraded from Strong Buy to Hold and Held Target at $108 on, Tuesday, January 12th, 2021
  • Colin Bristow of "UBS" Downgraded from Strong Buy to Hold on, Monday, January 11th, 2021
  • Danielle Brill of "Raymond James" Downgraded from Buy to Hold on, Friday, January 8th, 2021
  • Martin Auster of "Credit Suisse" Maintained at Hold with Decreased Target to $73 on, Friday, January 8th, 2021


These are the ratings of the 5 analyists that currently disagree with Matthew


  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $126 on, Tuesday, March 2nd, 2021
  • Difei Yang of "Mizuho" Maintained at Strong Buy with Increased Target to $160 on, Friday, February 26th, 2021
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy and Held Target at $135 on, Friday, February 26th, 2021
  • Anupam Rama of "JP Morgan" Downgraded from Buy to Sell and Held Target at $96 on, Friday, January 8th, 2021
  • Chad Messer of "Needham" Maintained at Strong Buy with Decreased Target to $166 on, Friday, January 8th, 2021